GARDP LogoGARDP: a not-for-profit research and development organization to address antimicrobial resistance

New R&D organization launched in partnership with WHO and incubated by DNDi



Public-private partnership to develop antibiotics for unmet needs and key populations

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit research and development organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access.

The World Health Organization (WHO) and DNDi launched GARDP in May 2016. DNDi thereafter incubated GARDP by providing the initial governance, scientific environment and infrastructure, as well as support for resource mobilization, communication, finance, and human resources.

During this incubation phase, GARDP built a skilled team and formed a Board of Directors with leading international experts. GARDP also formed numerous partnerships with industry, academia, and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis, and sexually-transmitted infections.

In July 2018, GARDP became an independent legal entity, which became operational in January 2019 following the successful three-year incubation.


Putting global public health needs first

Both organizations have a strong interest in sharing resources and knowledge, and so we will continue to collaborate closely:

  • sharing specialized R&D expertise and capacity (including discovery, pharmaceutical development, translational science, pharmacovigilance, and quality assurance);
  • in-country implementation of GARDP’s programmes will be supported by our international network and a joint DNDi GARDP office in Southern Africa;  
  • sharing a common approach on global health policy for promoting and contributing to public health needs-driven R&D and access; and
  • sharing infrastructure, including headquarters, and some support services to ensure value for money.


Marie Paule Kieny

“We’re proud to have provided the environment to enable GARDP to kickstart its mission to deliver antimicrobial research for patients. We look forward to a strong collaboration in sharing resources and knowledge with GARDP in the future, for the ultimate benefit of the populations served by GARDP and DNDi.”

Dr Marie-Paule Kieny, DNDi Board Chair


Incubation phase with the contribution of DNDi teams

  • GARDP was launched in May 2016.
  • GARDP received seed funding and pledges from the governments of Germany, Netherlands, South Africa, Switzerland, and the United Kingdom of Great Britain and Northern Ireland as well as from the medical humanitarian organization Médecins Sans Frontières / Doctors Without Borders (MSF).
  • DNDi provided the initial governance, scientific environment and infrastructure, as well as support for resource mobilization, communication, finance, and human resources necessary for an effective start-up phase. 
  • By early 2017, GARDP had secured EUR 6.5 million in seed funding, built a team of 10 people, facilitated 11 expert meetings in six countries on specific disease areas, regional issues, project reviews, and sustainable access.
  • In May, a Scientific Advisory Committee of  experts in various disciplines within infectious diseases and microbiology was set up.
  • With their expert review and DNDi’s Board of Directors’ approval, GARDP launched four programmes: neonatal sepsis; sexually-transmitted infections; antimicrobial memory recovery, evaluation and exploratory research; and paediatric antibiotics.
  • In July, GARDP signed its first partnering deal with Entasis Therapeutics to develop a new treatment for drug-resistant gonorrhoea.
  • In September, the German government hosted a pledging event for GARDP, a number of countries and foundations pledged more than EUR 56 million to GARDP.
  • In December, DNDi’s Board of Directors reaffirmed the creation of an independent legal entity for GARDP.
  • GARDP completed recruitment of key R&D positions, including its first R&D Director, enabling GARDP to continue delivering its programmes at pace.
  • GARDP started the first of its clinical trials: a phase I clinical trial on fosfomycin and a food effect trial to inform a phase III clinical trial for a novel, first-in-class oral antibiotic to treat gonorrhoea.
  • Over 80 researchers from 11 countries gathered in New Delhi to kick-off a global observational study for newborns with sepsis. Data generated from the study will be used to evaluate future interventions for this vulnerable population.
  • Several new public and private partnerships were formed, including with Takeda and Eisai, Sandoz (the Novartis generics division), and the University of Liverpool.
  • In July, GARDP was registered as an independent Swiss Foundation with a Board of Directors comprising leading international experts in the global health arena.